Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
ZIAGEN is an oral small-molecule antiviral approved in 1998 for HIV infection and psoriasis. The mechanism of action involves viral replication inhibition, though specific details are not fully characterized in available documentation. It represents a foundational treatment option in the antiretroviral and dermatologic therapeutic spaces.
Minimal commercial momentum with near-zero linked roles; team likely consolidating ahead of LOE.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ZIAGEN® Post-marketing Surveillance
ZIAGEN offers minimal career advancement opportunity due to minimal market presence (176 Part D claims, $112K spending in 2023) and approaching loss of exclusivity. Working on this product typically involves legacy management, cost containment, and transition planning rather than growth or innovation.
Worked on ZIAGEN at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo